A New Scoring System to Predict Recurrent Disease in Grade 1 and 2 Nonfunctional Pancreatic Neuroendocrine Tumors

Autor: Anneke P. J. Jilesen, S. van Eeden, F. J. van Kemenade, Stefano Partelli, Francesca Muffatti, S. van Dieren, Cansu Guney Genc, J. Verheij, E. J. M. Nieveen van Dijkum, Massimo Falconi, C.H.J. van Eijck
Přispěvatelé: Surgery, CCA - Cancer Treatment and Quality of Life, Pathology, APH - Methodology, AGEM - Digestive immunity, Genc, C. G., Jilesen, A. P., Partelli, S., Falconi, M., Muffatti, F., Van Kemenade, F. J., Van Eeden, S., Verheij, J., Van Dieren, S., Van Eijck, C. H. J., Nieveen Van Dijkum, E. J. M.
Rok vydání: 2018
Předmět:
Zdroj: Annals of surgery, 267(6). Lippincott Williams and Wilkins
Annals of Surgery, 267(6), 1148-1154. Lippincott Williams & Wilkins
ISSN: 1528-1140
0003-4932
DOI: 10.1097/sla.0000000000002123
Popis: Objective: The aim of this study was to predict recurrence in patients with grade 1 or 2 nonfunctioning pancreatic neuroendocrine tumors (NF-pNET) after curative resection. Background: Surgical resection is the preferred treatment for NF-pNET; however, recurrence occurs frequently after curative surgery, worsening prognosis of patients. Methods: Retrospectively, patients with NF-pNET of 3 institutions were included. Patients with distant metastases, hereditary syndromes, or grade 3 tumors were excluded. Local or distant tumor recurrence was scored. Independent predictors for survival and recurrence were identified using Cox-regression analysis. The recurrence score was developed to predict recurrence within 5 years after curative resection of grade 1 to 2 NF-pNET. Results: With a median follow-up of 51 months, 211 patients with grade 1 to 2 NF-pNET were included. Thirty-five patients (17%) developed recurrence. The 5- and 10-year disease-specific/overall survival was 98%/91% and 84%/68%, respectively. Predictors for recurrence were tumor grade 2, lymph node metastasis, and perineural invasion. On the basis of these predictors, the recurrence score was made. Discrimination [c-statistic 0.81, 95% confidence interval (95% CI) 0.75-0.87] and calibration (Hosmer Lemeshow Chi-square 11.25, P = 0.258) indicated that the ability of the recurrence score to identify patients at risk for recurrence is good. Conclusions: This new scoring system could predict recurrence after curative resection of grade 1 and 2 NF-pNET. With the use of the recurrence score, less extensive follow-up could be proposed for patients with low recurrence risk. For high-risk patients, clinical trials should be initiated to investigate whether adjuvant therapy might be beneficial. External validation is ongoing due to limited availability of adequate cohorts.
Databáze: OpenAIRE